Potential co-mutations known to affect the immune microenvironment, such as STK11/KEAP1, are known to reduce the benefit derived from immune checkpoint inhibitors in KRAS-mutant NSCLC. This evidence concerns the gene STK11 and non-small cell lung carcinoma.